PIB TrackerA 1,200-person Ashwagandha trial reports the absence of harm
Twenty-four weeks, seven sites, nine institutions, a peer-reviewed journal. The immunology result is that nothing happened - and that is being reported as a finding.
What happened
- A multicentre randomised double-blind placebo-controlled trial of standardised Ashwagandha root extract published in Frontiers in Medicine, 20 August 2026.
- 1,200 adults aged 18-70, all COVISHIELD-vaccinated, randomised to 500 mg daily (equal to 4 g raw root powder) or placebo across seven sites; 1,032 (86%) completed.
- No evidence of treatment-related liver or kidney injury - enzymes, bilirubin, creatinine and blood urea within reference ranges over 24 weeks.
- Virus-neutralising activity exceeded 85% in both groups, with no statistically significant difference.
- Conducted by 45 researchers from nine institutions including CCRAS, the All India Institute of Ayurveda, NIA Jaipur and THSTI; registered as CTRI/2021/06/034496.
For Prelims
- Why hepatotoxicity was the question: Ashwagandha has faced liver-safety concerns internationally, and several regulators have acted on them. A 24-week controlled trial testing exactly that is a direct response to a specific criticism, not a general study.
- Ashwagandha: Withania somnifera, classified in Ayurveda as a Rasayana - a rejuvenative. The trial used a standardised aqueous root extract, not the whole herb.
- Standardisation is the whole point: 500 mg of extract stated as equivalent to 4 g of raw root powder is an 8:1 concentration. A safety result for a standardised extract does not transfer to unstandardised products.
- CTRI: the Clinical Trials Registry-India, maintained by ICMR. Prior registration - here CTRI/2021/06/034496 - is what makes a trial's design auditable against its published result.
- Double-blind, placebo-controlled, randomised: neither participant nor investigator knows the allocation, an inert comparator is used, and assignment is by chance. This is the design that removes expectation from the result.
- Reading a null result: "no statistically significant difference" between arms is an absence of effect, not a demonstration of safety in the immunological sense. Here it supports non-interference with vaccine-induced immunity - a useful claim, and a narrow one.
- The institutions: CCRAS is the apex Ayurveda research council under the Ministry of AYUSH; THSTI is an autonomous institute of the Department of Biotechnology - so the trial crosses the AYUSH and biotechnology systems.
- Attrition matters: 86% completion over 24 weeks is respectable for a long-duration trial, and the 168 who left are the population in which an unreported tolerability signal would hide.
For UPSC: This is the strongest available example of traditional medicine being tested by contemporary clinical standards, and it is quotable in both directions. Use it on integrating AYUSH into evidence-based healthcare, on research methodology and how to read a null result, on regulatory science for herbal products, and on institutional collaboration between AYUSH councils and biotechnology institutes.
What it is NOT: The trial is titled "prophylactic use" and the release reports no prophylaxis outcome at all - no infection rates, no symptomatic episodes, no comparison of illness between arms - so the question the title poses is not answered here. No efficacy endpoint of any kind is reported. No reason is given for the 168 participants who did not complete. No antibody titre values are given beyond "exceeded 85 per cent" in both arms. No manufacturer or product identity is stated for the standardised extract, which matters because the safety finding is specific to the preparation tested. And the trial was registered in June 2021 and published in August 2026, with no explanation of the gap.
For Mains
Syllabus: GS3.13 · GS2.13 · Linkage L2
Anchor
A trial of 1,200 people across seven sites over 24 weeks has reported its result: nothing happened. Liver enzymes, bilirubin, creatinine and blood urea stayed within reference ranges, no serious adverse event was attributed to the intervention, and virus-neutralising activity was statistically indistinguishable between the Ashwagandha and placebo arms. The entire finding is an absence, and in this case that is exactly what the study was built to establish.
Substantiation (data)
The methodology is the strongest part. Randomised, double-blind, placebo-controlled, seven centres, 45 researchers from nine institutions, prior registration with the Clinical Trials Registry-India, 24 weeks of intervention with follow-up to week 28, and publication in a peer-reviewed journal. The dose was 500 mg of a standardised aqueous root extract, stated as equal to 4 grams of raw root powder. Of 1,200 enrolled, 1,032 completed - 86 per cent.
Position
Absence of harm is a real and undervalued result, and this one answers a specific charge. Ashwagandha has faced liver-safety concerns abroad, and the honest reply to a toxicity question is a long-duration controlled trial with laboratory endpoints, not a claim about benefits. Running that trial on a standardised extract at a stated dose, registering it beforehand and publishing it in a journal is how a traditional-medicine claim is supposed to be defended.
Counterpoint
The immunology result is being presented more warmly than it reads. "Virus-neutralising activity exceeded 85 per cent in both groups, with no statistically significant difference" is a null result, and the lead author's framing - that Ashwagandha did not interfere with vaccine-induced immunity - is a correct but modest restatement of it. Non-interference is worth knowing; it is not a benefit, and the release does not say so plainly.
Problematisation
The study is titled prophylactic use and reports no prophylaxis. There is no infection rate, no count of symptomatic episodes, no comparison of who fell ill in which arm - the outcome a reader would expect from a trial registered in 2021 as prophylaxis following vaccination. It is entirely legitimate for a paper to report safety and tolerability alone. It is the release, not the paper, that carries a title promising one thing and a result delivering another.
Conclusion
Treat this as what it is: good evidence that a specific standardised extract at a specific dose does not damage the liver or kidneys over six months, and no evidence that it does anything. That distinction is the whole difference between regulatory reassurance and a therapeutic claim, and it is the one most reporting of this study will lose.
Deploys into: Evidence-based integration of AYUSH · Reading null results and safety endpoints · Regulatory science for standardised herbal extracts · Clinical trial registration and transparency
Ministry of AYUSH · 2026-09-28 · PRID 2315947 · PIB source ↗